Price Target Update on Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) : Currently there are 12 street experts covering Amgen (NASDAQ:AMGN) stock. The most bullish and bearish price target for the stock is $195 and $157 respectively for the short term. The average price target of all the analysts comes to $183.75. The estimated standard deviation from the target is $10.37.

Other Equity analysts have also commented on the company shares. BMO Capital initiates coverage on Amgen (NASDAQ:AMGN) The current rating of the shares is Outperform. Equity Analysts at the Firm announces the price target to $183 per share. The rating by the firm was issued on April 5, 2016.

Amgen (NASDAQ:AMGN): stock turned positive on Thursday. Though the stock opened at $151.21, the bulls momentum made the stock top out at $152.4 level for the day. The stock recorded a low of $150.63 and closed the trading day at $152.27, in the green by 1.64%. The total traded volume for the day was 3,000,423. The stock had closed at $149.81 in the previous days trading.

The company shares have dropped -5.64% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $181.81 and the one year low was seen on Sep 28, 2015. The 50-Day Moving Average price is $154.00 and the 200 Day Moving Average price is recorded at $153.39. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Balachandran Madhavan, officer (EVP, Operations) of Amgen Inc, had unloaded 30,000 shares at an average price of $154.12 in a transaction dated on May 4, 2016. The total value of the transaction was worth $4,623,600.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.